| Literature DB >> 23296178 |
Abstract
Researchers are trying to develop more efficient and safer antifracture treatments. Besides the ongoing promising clinical trials involving antibodies to the Wnt antagonist sclerostin or inhibition of the osteoclast enzyme cathepsin K, the year 2012 has seen several novel osteoporosis targets identified by using different methodological approaches.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23296178 DOI: 10.1038/nrendo.2012.252
Source DB: PubMed Journal: Nat Rev Endocrinol ISSN: 1759-5029 Impact factor: 43.330